A Case of SAPHO Syndrome Presenting as Isolated Iliitis and Spondylitis

To the Editor:
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome has a variable presentation and it is now believed that a number of previously described entities are cases of SAPHO. These include chronic recurrent multifocal osteomyelitis (CRMO) and pustulotic arthro-osteitis 1 . We describe a case of SAPHO presenting with iliitis and pyoderma gangrenosum as the sole manifestations.
A 39-year-old man was reviewed in the rheumatology outpatients department. He gave a history of episodic pain in both hips and his lower back since the age of 18 years. He had previously been diagnosed with HLA-B27-negative spondyloarthropathy at another center and had had a left hip replacement at the age of 22 years for secondary left hip osteoarthritis, and subsequently a revision of this at the age of 36 years when he fractured his left femur in a fall. He had developed a pyoderma gangrenosum at age 38 years. His clinical history and laboratory, radiological, and pathological investigations were reviewed. He had had persistently elevated inflammatory markers over the years, his latest erythrocyte sedimentation rate was 76 mm/h, C-reactive protein 73 mg/l, hemoglobin 10.2 g/dl, and platelets 596 × 10 9 /l. Serum protein electrophoresis revealed a polyclonal gammopathy. Alkaline phosphatase was mildly elevated at 161 IU/l; the remainder of his biochemistry and hematology was normal. Plain radiography revealed severe chronic sclerotic change in the left hemipelvis ( Figure 1 ). An isotope bone scan demonstrated increased activity in the left hemipelvis. Two previous bone biopsies had been reported as showing nonspecific focal inflammatory changes with negative cultures.
A provisional diagnosis of SAPHO syndrome was made. Computed tomography (CT) and magnetic resonance imaging (MRI) scans and a repeat bone biopsy of the left sacrum were performed in light of the clinical suspicion. CT ( Figure 2 ) and MRI demonstrated marked osteitis in the left hemipelvis and sacral spine, with involvement extending to the L5 vertebra. The sacral biopsy demonstrated changes consistent with osteomyelitis. Microscopy and cultures including TB cultures and cultures for Propionibacterium acnes were negative. This confirmed the diagnosis of SAPHO. Treatment with nonsteroidal antiinflammatory drugs (NSAID) and intravenous pamidronate was commenced, with marked clinical improvement.
The initial diagnostic criteria proposed in 1987 are still used for SAPHO syndrome. The inclusion criteria comprise osteoarticular manifestations of severe acne or palmoplantar pustulosis; hyperostosis of the anterior chest wall, limb, or spine; or chronic recurrent multifocal osteomyelitis. Exclusion criteria include infectious osteomyelitis or arthritis (except P. acnes), diffuse idiopathic skeletal hyperostosis (DISH), palmoplantar keratoderma, and osteoarticular manifestations of retinoid therapy 2, 3 . The differential diagnosis of SAPHO is shown in Table 1 .
SAPHO is at present considered a rare disease but the true prevalence Computed tomography scan of the lumbosacral junction at the level of the S1 vertebra shows marked mixed sclerotic and lucent, almost "moth-eaten" appearance of S1 vertebra, adjacent ilium, and the posterior elements of L5. In addition there is fusion of the sacroiliac joint.
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The on October 19, 2017 -Published by www.jrheum.org Downloaded from Letter is probably underestimated. SAPHO has a female predominance 4 . Clinical presentation is dependent on the features present in a particular case. Bony lesions cause significant pain, with associated swelling at superficial sites. The anterior chest wall is the most common site, followed by the spine, but they can occur at virtually any bony site. Classic skin lesions include acne fulminans, hidradenitis suppurativa, and palmoplantar pustulosis. Less commonly described dermatological manifestations include pyoderma gangrenosum 5 , as in our case, and Sweet's syndrome. An association with inflammatory bowel disease has been reported in some series 6 . The clinical course is commonly marked by exacerbations and remissions; how ever, there may also be ongoing low-grade features throughout the course, as in our case.
Acute-phase reactants may be elevated, as in our case, but sometimes are not 4 . An association with HLA-B27 has been suggested; however, recent case series 4 indicate it to be no more frequent than in the general population.
Plain radiography demonstrates osteolysis in early cases, progressing to sclerotic changes in advanced disease. In very early disease, plain radiographs can be normal. Isotope bone scans demonstrate increased uptake in areas of active disease. SAPHO often has a characteristic appearance on MRI, with high signal on fat-saturated T2 fast spin-echo sequences and low signal on T1-weighted imaging, which enhances with gadolinium 7 , as in our case.
Bone biopsy is performed mainly to exclude infection and malignancy. There are no pathognomonic features of SAPHO on biopsy. Characteristically early lesions show inflammatory infiltrate with polymorphonuclear cells progressing to an infiltrate composed predominantly of lymphocytes and plasma cells. Noncaseating granulomas and multinucleate giant cells can also be seen. Chronic lesions may demonstrate fibrosis and new bone formation 8 . P. acnes has rarely been found at biopsy.
The treatment of SAPHO is largely based on case studies and expert opinion due to the rarity of the condition. NSAID are the first-line treatment employed in almost all patients. Steroids are usually effective in the short term, but can be associated with relapses following treatment withdrawal. Bisphosphonates, in particular pamidronate, appear to be particularly effective in the treatment of resistant cases of SAPHO 9 . The use of macrolide antibiotics such as azithromycin has been reported; they are thought to exert their effects through immunomodulatory rather than antibacterial mechanisms. Traditional disease-modifying antirheumatic drugs, particularly sulfasalazine and methotrexate, have a role in refractory cases. There have been reports of responses to anti-tumor necrosis factor agents 10 .
Our case demonstrates the need for awareness of atypical presentations of SAPHO syndrome, the potentially destructive course of untreated disease, and the dramatic response to targeted treatment once the diagnosis is made.
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